Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 6, 2012, Pages 619-634

  Nielsen, Jace C ^a   Hutmacher, Matthew M ^a   Cleton, Adriaan ^b,e   Martin, Steven W ^c   Ribbing, Jakob ^d  

^a ANN ARBOR PHARMACOMETRICS GROUP   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d PFIZER INC   (United States)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

COPD; CRC 749; Dry powder inhaler; FEV1; K PD; LABA; NONMEM; PF 00610355; PF 610355; Salmeterol

Indexed keywords

PF 00610355; PLACEBO; RESPIRATORY TRACT AGENT; SALMETEROL; UNCLASSIFIED DRUG;

ARTICLE; CALCULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; FORCED EXPIRATORY VOLUME; HUMAN; LONGITUDINAL STUDY; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; META ANALYSIS; PRIORITY JOURNAL; PROBABILITY; SIMULATION; SINGLE DRUG DOSE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; CIRCADIAN CLOCKS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LONGITUDINAL STUDIES; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84880710548     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9274-0     Document Type: Article

References (23)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverlay P et al (2007) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532-555 (Pubitemid 47403272)
2. 2 adrenoreceptor agonist with a long duration of action. Eur Respir J 34:Suppl 53
3. 2- adrenoreceptor agonist for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J Med Chem 53(18):6640-6652
4. Jacqmin P, Snoeck E, van Schaick EA, Gieschke R, Pillai P, Steimer JL, Girard P (2006) Modeling response time profiles in the absence of drug concentrations; definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn 34:57-85 (Pubitemid 46122548)
5. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2007) p 3. http://www.goldcopd.org/uploads/users/files/GOLDReport07-0108.pdf
6. Vestbo J, Tan L, Atkinson G, Ward J (2009) A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J 33:1039-1044
7. Beal SL, Sheiner LB (1992) NONMEM users guide, NONMEM Project Group. University of California, San Francisco
8. SAS Institute Inc (2002) SAS software: usage and reference, version 9. SAS Institute Inc., Cary
9. TIBCO (2010) Spotfire S+ 8.2 for windows user's guide. TIBCO Software Inc., Palo Alto
10. Wu K, Looby M, Pillai G, Pinault G, Drollman AF, Pascoe S (2010) Population pharmacodynamic model of the longitudinal FEV1 response to inhaled long-acting anti-muscarinic in COPD patients. J Pharmacokinet Pharmacodyn 38:105-119
11. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A et al (2010) Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 182:155-162
12. Borsboom GJJM, van Pelt W, van Houwelingen HC, van Vianen BG, Schouten JP, Quanjer PH (1999) Diurnal variation in lung function in subgroups from two dutch populations: consequences for longitudinal analysis. Am J Respir Crit Care Med 159:1163-1171 (Pubitemid 29202551)
13. Medarov BI, Pavlov VA, Rossoff L (2008) Diurnal variations in human pulmonary function. Int J Clin Exp Med 1:267-273
14. Calverlay PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S (2003) Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 58:855-860 (Pubitemid 37239232)
15. Cazzola M, Matera MG (2009) Emerging inhaled bronchodilators: an update. Eur Respir J 34:757-769
16. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. doi: 10.1208/s12248-011-9255-z
17. Ribbing J, Falcoz C, Correa I, Martin SW (2012) Literature model for FEV1 in COPD trials: separating the dynamic components of placebo effect, disease progression and interacting drug effects. PAGE 21, Venice. Abstr 2530 http://www.page-meeting.org/?abstract=2530. Accessed 6 June 2012
18. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ et al (2008) Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 31:416-468
19. Calverley PM, Rennard SI (2007) What have we learned from large drug treatment trials in COPD? Lancet 370:774-785 (Pubitemid 47320801)
20. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT et al (2009) Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomized, placebo-controlled TORCH study. Respir Res 10:59
21. European Medicines Agency (2009) Evaluation of medicines for human use: assessment report for Hirobriz Breezhaler (Doc. Ref: EMA/814999/2009). London. http://www.emea.europa.eu/docs/en-GB/document-library/EPARPublic-assessment- report/human/001211/WC500051168.pdf. Accessed 17 December 2009
22. Renard D, Looby M, Kramer B, Lawrence D, Morris D, Stanski DR (2011) Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disesase using model-based approaches. Respir Res 12:54
23. Wang Y, Lee JY, Michele T, Chowdhury BA, Gobburu JV. Limitations of model based dose selection for indacaterol in patients with chronic obstructive pulmonary disease. Int J Cin Pharm Ther. 2012 May 14